uniQure NV (NASDAQ:QURE) dropped 3.2% during trading on Wednesday . The stock traded as low as $7.58 and last traded at $7.67, with a volume of 88,307 shares changing hands. The stock had previously closed at $7.92.

QURE has been the topic of several recent analyst reports. WallachBeth Capital dropped their price objective on uniQure NV from $60.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, June 15th. Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. Leerink Swann reaffirmed a “buy” rating on shares of uniQure NV in a research report on Sunday, June 12th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of uniQure NV in a research report on Monday, June 13th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $28.10.

The company’s market cap is $194.75 million. The company has a 50-day moving average of $8.23 and a 200-day moving average of $10.38.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/uniqure-nv-qure-shares-down-3-2.html

uniQure NV (NASDAQ:QURE) last released its quarterly earnings results on Thursday, August 25th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.02. uniQure NV had a negative return on equity of 61.96% and a negative net margin of 537.62%. On average, analysts expect that uniQure NV will post ($3.71) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Institutional Trust Company N.A. increased its position in shares of uniQure NV by 1,350.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 23,417 shares of the company’s stock valued at $173,000 after buying an additional 21,802 shares during the period. BlackRock Fund Advisors increased its position in shares of uniQure NV by 7.4% in the second quarter. BlackRock Fund Advisors now owns 315,775 shares of the company’s stock valued at $2,327,000 after buying an additional 21,657 shares during the period. Acrospire Investment Management LLC increased its position in shares of uniQure NV by 355.2% in the second quarter. Acrospire Investment Management LLC now owns 17,298 shares of the company’s stock valued at $127,000 after buying an additional 13,498 shares during the period. JPMorgan Chase & Co. increased its position in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock valued at $104,000 after buying an additional 5,760 shares during the period. Finally, Princeton Alpha Management LP acquired a new position in shares of uniQure NV during the second quarter valued at $120,000. 32.38% of the stock is owned by hedge funds and other institutional investors.

uniQure NV Company Profile

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

5 Day Chart for NASDAQ:QURE

Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.